Log in to search using one of your social media accounts:

 

Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer.
CONCLUSION: We developed a clinically relevant signature for patients with chemoresistant TNBC. For these women, new therapeutic strategies like targeting AR activation or cancer stem cells may need to be developed. Clin Cancer Res; 19(10); 2723-33. ©2013 AACR. PMID: 23549873 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 15, 2013 Category: Cancer & Oncology Authors: Yu KD, Zhu R, Zhan M, Rodriguez AA, Yang W, Wong S, Makris A, Lehmann BD, Chen X, Mayer I, Pietenpol JA, Shao ZM, Symmans WF, Chang JC Tags: Clin Cancer Res Source Type: research

Relapsed Classic E-Cadherin (CDH1)-Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations.
CONCLUSIONS: Comprehensive genomic profiling of relapsed CDH1-mutated ILC revealed actionable genomic alterations in 86% of cases, featured a high incidence of ERBB2 alterations, and can reveal actionable alterations that can inform treatment decisions for patients with ILC. Clin Cancer Res; 19(10); 2668-76. ©2013 AACR. PMID: 23575477 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 15, 2013 Category: Cancer & Oncology Authors: Ross JS, Wang K, Sheehan CE, Boguniewicz AB, Otto G, Downing SR, Sun J, He J, Curran JA, Ali S, Yelensky R, Lipson D, Palmer G, Miller VA, Stephens PJ Tags: Clin Cancer Res Source Type: research

Prognostic Role of Human Epidermal Growth Factor Receptor 2 Status in Premenopausal Early Breast Cancer Treated With Adjuvant Tamoxifen.
CONCLUSIONS: Resistance to tamoxifen is a complex trait, and its pathway is still unclear; in patients with BC, a multidisciplinary approach is highly recommended. In our experience, we did not find a statistically significant difference in tamoxifen treatment efficacy according to HER2 status. PMID: 23684167 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 14, 2013 Category: Cancer & Oncology Authors: Meattini I, Livi L, Saieva C, Franceschini D, Scotti V, Mangoni M, Loi M, Brina LD, Zei G, Bonomo P, Greto D, Gelain E, Nori J, Sanchez LJ, Orzalesi L, Bianchi S, Biti G Tags: Clin Breast Cancer Source Type: research

Comparison of Two Radiotherapeutic Hypofractionated Schedules in the Application of Tumor Bed Boost.
Abstract AIM: Evaluation of related radiation toxicity and efficacy in terms of local control of 2 radiotherapeutic hypofractionated schedules in the application of tumor bed boost by using 2 different planning techniques. METHOD: Eighty-one patients with stage I-II disease were retrospectively selected with either concomitant (group A) or sequential (group B) boost for the tumor bed. In group A, 27 patients were treated with a total dose of 46 Gy to the whole breast and 54 Gy to the tumor bed in 20 concomitant fractions. In group B, 54 patients were treated with a total dose of 42.4 Gy in 16 fractions to the whol...
Source: Clinical Breast Cancer - May 14, 2013 Category: Cancer & Oncology Authors: Zygogianni A, Kouloulias V, Kyrgias G, Armpilia C, Antypas C, Theodorou K, Kouvaris J Tags: Clin Breast Cancer Source Type: research

Intraductal Therapy of Ductal Carcinoma In Situ: A Presurgery Study.
CONCLUSIONS: Intraductal therapy offers a nonsurgical strategy to treat DCIS at the site of disease, potentially minimizing the adverse effects of systemic treatment while preventing development of invasive cancer. PMID: 23664819 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 9, 2013 Category: Cancer & Oncology Authors: Mahoney ME, Gordon EJ, Rao JY, Jin Y, Hylton N, Love SM Tags: Clin Breast Cancer Source Type: research

Cognitive Training for Improving Executive Function in Chemotherapy-Treated Breast Cancer Survivors.
CONCLUSIONS: Our findings suggest that EF skills may be improved even in long-term survivors by using a computerized, home-based intervention program. These improvements may potentially include subjective EF skills, which suggest a transfer of the training program to real-world behaviors. PMID: 23647804 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 3, 2013 Category: Cancer & Oncology Authors: Kesler S, Hosseini SM, Heckler C, Janelsins M, Palesh O, Mustian K, Morrow G Tags: Clin Breast Cancer Source Type: research

Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease.
CONCLUSION: Bazedoxifene was recently approved for use in the European Union for the treatment of osteoporosis and thus may represent a near-term therapeutic option for patients with advanced breast cancer. Clin Cancer Res; 19(9); 2420-31. ©2013 AACR. PMID: 23536434 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 1, 2013 Category: Cancer & Oncology Authors: Wardell SE, Nelson ER, Chao CA, McDonnell DP Tags: Clin Cancer Res Source Type: research

Quantitative ultrasound evaluation of tumor cell death response in locally advanced breast cancer patients receiving chemotherapy.
This study investigates for the first time the potential of early detection of tumor cell death in response to clinical cancer therapy administration in patients using quantitative ultrasound spectroscopic methods. EXPERIMENTAL DESIGN: Patients (n = 24) with locally advanced breast cancer received neoadjuvant chemotherapy treatments. Ultrasound data were collected before treatment onset and at 4 times during treatment (weeks 1, 4, and 8, and preoperatively). Quantitative ultrasound parameters were evaluated for clinically responsive and nonresponding patients. RESULTS: Results indicated that quantitative ultrasou...
Source: Clinical Breast Cancer - April 15, 2013 Category: Cancer & Oncology Authors: Sadeghi-Naini A, Papanicolau N, Falou O, Zubovits J, Dent R, Verma S, Trudeau M, Boileau JF, Spayne J, Iradji S, Sofroni E, Lee J, Lemon-Wong S, Yaffe M, Kolios MC, Czarnota GJ Tags: Clin Cancer Res Source Type: research

Abcc4 Together with Abcb1 and Abcg2 Form a Robust Cooperative Drug Efflux System That Restricts the Brain Entry of Camptothecin Analogues.
CONCLUSION: Abcc4 limits the brain penetration of camptothecin analogues and teams up with Abcb1a/b and Abcg2 to form a robust cooperative drug efflux system. This concerted action limits the usefulness of selective ABC transport inhibitors to enhance drug entry for treatment of intracranial diseases. Our results also suggest that gimatecan might be a better candidate than irinotecan for clinical evaluation against intracranial tumors. Clin Cancer Res; 19(8); 2084-95. ©2013 AACR. PMID: 23461902 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 15, 2013 Category: Cancer & Oncology Authors: Lin F, Marchetti S, Pluim D, Iusuf D, Mazzanti R, Schellens JH, Beijnen JH, van Tellingen O Tags: Clin Cancer Res Source Type: research

Mammographic breast density response to aromatase inhibition.
CONCLUSIONS: In postmenopausal women treated with aromatase inhibitors, 14% of cases had a MBD reduction of more than 5%, but these decreases did not differ from matched controls. These data suggest that MBD is not a clinically useful biomarker for predicting the value of aromatase inhibitor therapy in White postmenopausal women. Clin Cancer Res; 19(8); 2144-53. ©2013 AACR. PMID: 23468058 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 15, 2013 Category: Cancer & Oncology Authors: Vachon CM, Suman VJ, Brandt KR, Kosel ML, Buzdar AU, Olson JE, Wu FF, Flickinger LM, Ursin G, Elliott CR, Shepherd L, Weinshilboum RM, Goss PE, Ingle JN Tags: Clin Cancer Res Source Type: research

A Targeted RNAi Screen of the Breast Cancer Genome Identifies KIF14 and TLN1 as Genes That Modulate Docetaxel Chemosensitivity in Triple-Negative Breast Cancer.
CONCLUSION: KIF14 and TLN1 are modulators of response to docetaxel and potential therapeutic targets in TNBC. Clin Cancer Res; 19(8); 2061-70. ©2013 AACR. PMID: 23479679 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 15, 2013 Category: Cancer & Oncology Authors: Singel SM, Cornelius C, Batten K, Fasciani G, Wright WE, Lum L, Shay JW Tags: Clin Cancer Res Source Type: research

Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: Long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials.
eeweiss A Abstract We previously reported primary endpoints of two consecutive phase I/II trials, evaluating different schedules of neoadjuvant epirubicin (E), gemcitabine (G) and docetaxel (Doc) for primary breast cancer (PBC). Here, we report mature survival data and prognostic factors. One hundred fifty-one patients were recruited into two consecutive phase I/II trials of neoadjuvant chemotherapy for T2-4 N0-2 M0 PBC. Patients received six cycles of G/E/Doc every 3 weeks with G repeated on d8 (GEDoc, n = 84) or five cycles of G/E followed by four cycles of Doc all given every two weeks (GEsDoc, n&...
Source: Clinical Breast Cancer - February 7, 2013 Category: Cancer & Oncology Authors: Marmé F, Aigner J, Lorenzo Bermejo J, Sinn P, Sohn C, Jäger D, Schneeweiss A Tags: Int J Cancer Source Type: research

A New Technique That Complements Sentinel Lymph Node Biopsy: Lymph Node Dissection Under the Intercostobrachial Nerves in Early-Stage Breast Cancer.
CONCLUSION: ALND under the ICBN could be considered a procedure complementary to SLNB in early-stage breast cancer in China, where the radioactive tracer technique is not widely applied. PMID: 23380290 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 1, 2013 Category: Cancer & Oncology Authors: Li J, Jia S, Zhang W, Zhang Y, Qiu F, Xue J, Gu X Tags: Clin Breast Cancer Source Type: research

Tumor Grade and Matrix Metalloproteinase 2 Expression in Stromal Fibroblasts Help to Stratify the High-Risk Group of Patients With Early Breast Cancer Identified on the Basis of St Gallen Recommendations.
CONCLUSION: To the best of our knowledge, we have shown for the first time that MMP-2(-) in stromal fibroblasts might indicate poor survivors in the group of patients with grade 3 tumors and that the cumulative effect of both above-mentioned parameters might be helpful in selecting the high-risk individuals from the group of patients with luminal B subtype/HER2(+)/triple negative phenotype identified according to St Gallen recommendations. PMID: 23375518 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 30, 2013 Category: Cancer & Oncology Authors: Niemiec J, Adamczyk A, Małecki K, Ambicka A, Ryś J Tags: Clin Breast Cancer Source Type: research

Favorable Changes in Serum Estrogens and Other Biologic Factors After Weight Loss in Breast Cancer Survivors Who Are Overweight or Obese.
This study aimed to assess the effects of weight loss on these factors. PATIENTS AND METHODS: Breast cancer survivors who were overweight or obese (n = 220) and who were enrolled in a weight loss intervention study provided baseline and follow-up blood samples and weight data. Serum estrogens, SHBG, insulin, and leptin were measured at baseline, 6 months, and 18 months. RESULTS: Weight loss of ≥5% of initial weight decreased leptin and insulin compared with those who did not achieve that amount of weight loss (P
Source: Clinical Breast Cancer - January 29, 2013 Category: Cancer & Oncology Authors: Rock CL, Pande C, Flatt SW, Ying C, Pakiz B, Parker BA, Williams K, Bardwell WA, Heath DD, Nichols JF Tags: Clin Breast Cancer Source Type: research

Prophylactic Mastectomy in Patients at High Risk: Is There a Role for Sentinel Lymph Node Biopsy?
CONCLUSION: Although a minimally invasive procedure, the utility of SLNB in patients with absent or contralateral early disease is limited. Advanced T stage, multicentricity, or receptor status on the therapeutic side or a finding of in situ or atypical hyperplasia in prophylactic breast specimen yielded no positive SLN. Routine SLNB in pure bilateral PM can safely be omitted, which reduces axillary morbidity and operative time and/or cost. Selective use of SLNB for contralateral recurrent and/or locally advanced cancers warrants further investigation. PMID: 23357305 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 25, 2013 Category: Cancer & Oncology Authors: Murthy V, Chamberlain RS Tags: Clin Breast Cancer Source Type: research

Final Results from Phase II Trial of Neoadjuvant Docetaxel and Capecitabine Given Sequentially or Concurrently for HER2-Negative Breast Cancers.
CONCLUSION: The combination of docetaxel and capecitabine has modest activity in the neoadjuvant setting. These results are consistent with other trials using this combination in the neoadjuvant setting. PMID: 23332349 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 15, 2013 Category: Cancer & Oncology Authors: Zelnak AB, Styblo TM, Rizzo M, Gabram SG, Wood WC, Harichand-Herdt S, Kim S, Liu Y, O'Regan RM, Georgia Center for Oncology Research and Education Tags: Clin Breast Cancer Source Type: research

The Role of Immunohistochemistry in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: An Old Tool With an Enduring Prognostic Value.
Perez V, Alba-Conejo E, Sánchez-Rovira P Abstract BACKGROUND: To assess the molecular subtypes determined by hormonal receptors (HR) and human epidermal growth factor receptor 2 (HER2) status and the role of proliferation measured by the Ki-67 marker as predictive and prognostic factors in breast cancer patients treated with neoadjuvant chemotherapy. METHODS: A total of 127 breast cancer patients were treated with neoadjuvant chemotherapy every 2 weeks as part of 2 studies. Study A consisted of the administration of Adriamycin (40 mg/m(2)) on day 1 plus paclitaxel (150 mg/m(2)) and gemcitabine 2000 mg/m(2))...
Source: Clinical Breast Cancer - January 10, 2013 Category: Cancer & Oncology Authors: Sánchez-Muñoz A, Plata-Fernández YM, Fernández M, Jaén-Morago A, Fernández-Navarro M, de la Torre-Cabrera C, Ramirez-Tortosa C, Lomas-Garrido M, Llácer C, Navarro-Perez V, Alba-Conejo E, Sánchez-Rovira P Tags: Clin Breast Cancer Source Type: research

Simple Mastectomy and Axillary Lymph Node Biopsy Performed Under Paravertebral Block and Light Sedation in a Patient with Severe Cardiorespiratory Comorbidities: Proposed Management of Choice in High-Risk Breast Surgery Patients.
PMID: 23290077 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 2, 2013 Category: Cancer & Oncology Authors: Bugelli GJ, Samra WA, Stuart-Smith K Tags: Clin Breast Cancer Source Type: research

The Tetrad BMI, Leptin, Leptin/Adiponectin (L/A) Ratio and CA 15-3 are Reliable Biomarkers of Breast Cancer.
CONCLUSION: When the four variables were analysed together, a sensitivity of 83.3%, specificity of 80%, positive predictive value of 83.3% and negative predictive value of 80% were obtained. Results indicate that using the 75th percentile set points for BMI, leptin, L/A ratio and CA 15-3 together could offer a reliable approach to determine which women are at high risk for developing breast cancer. PMID: 23292756 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 1, 2013 Category: Cancer & Oncology Authors: Santillán-Benítez JG, Mendieta-Zerón H, Gómez-Oliván LM, Torres-Juárez JJ, González-Bañales JM, Hernández-Peña LV, Ordóñez-Quiroz A Tags: J Clin Lab Anal Source Type: research

Resistance to Trastuzumab in HER2-Positive Mucinous Invasive Ductal Breast Carcinoma.
PMID: 23276464 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 28, 2012 Category: Cancer & Oncology Authors: Baretta Z, Guindalini RS, Khramtsova G, Olopade OI Tags: Clin Breast Cancer Source Type: research

A Pooled Analysis of 2618 Patients Treated with Trastuzumab Beyond Progression for Advanced Breast Cancer.
CONCLUSIONS: This pooled analysis confirms that continuing T beyond the first progression continues to be 1 of the effective and preferred choices in HER2+ MBC, failing a (T-based) first-line regimen. PMID: 23276465 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 28, 2012 Category: Cancer & Oncology Authors: Petrelli F, Barni S Tags: Clin Breast Cancer Source Type: research

Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study.
CONCLUSIONS: After docetaxel treatment, the majority of patients experienced disappearance of DTCs. As this is not a randomized trial, the results can be due to effects of adjuvant (docetaxel/endocrine/trastuzumab) treatment and/or limitations of the methodology. The clinical significance of these results awaits mature FU data, but indicates a possibility for clinical use of DTC-status as a residual disease-monitoring tool and as a surrogate marker of treatment response.Trial registration: Clin Trials Gov NCT00248703. PMID: 23259667 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 22, 2012 Category: Cancer & Oncology Authors: Synnestvedt M, Borgen E, Wist E, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Schirmer C, Nesland JM, Naume B Tags: BMC Cancer Source Type: research

Immunohistochemically Defined Subtypes and Outcome of Apocrine Breast Cancer.
CONCLUSION: Pure apocrine carcinoma represents a distinct subtype of breast cancer with a significantly worse DFS as compared with IDC. AR determination might have an important prognostic implication in IAC. Moreover, AR-targeted therapy should be further explored within these tumors. PMID: 23245877 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 13, 2012 Category: Cancer & Oncology Authors: Dellapasqua S, Maisonneuve P, Viale G, Pruneri G, Mazzarol G, Ghisini R, Mazza M, Iorfida M, Rotmensz N, Veronesi P, Luini A, Goldhirsch A, Colleoni M Tags: Clin Breast Cancer Source Type: research

Breast Preservation in Women With Giant Juvenile Fibroadenoma.
PMID: 23245878 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 13, 2012 Category: Cancer & Oncology Authors: Matz D, Kerivan L, Reintgen M, Akman K, Lozicki A, Causey T, Clynes C, Giuliano R, Acs G, Cox J, Cox C, Reintgen D Tags: Clin Breast Cancer Source Type: research

Prognostic Markers for Invasive Micropapillary Carcinoma of the Breast: A Population-Based Analysis.
This study of 624 patients diagnosed with breast IMPC (2001-2008) listed in the National Cancer Institute's Surveillance, Epidemiology, and End Results (NCI SEER) database was performed to evaluate prognostic factors for disease-specific survival (DSS) and overall survival (OS). RESULTS: The 5-year DSS and OS for patients with IMPC were 91.9% and 83.8%, respectively. Of those with known estrogen receptor (ER) status, 84.8% were ER-positive (ER(+)), which was associated with better DSS (hazard ratio [HR], 0.27; P
Source: Clinical Breast Cancer - December 12, 2012 Category: Cancer & Oncology Authors: Chen AC, Paulino AC, Schwartz MR, Rodriguez AA, Bass BL, Chang JC, Teh BS Tags: Clin Breast Cancer Source Type: research

Changing Concepts of Hormone Receptor-Positive Advanced Breast Cancer Therapy.
PMID: 23228361 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 7, 2012 Category: Cancer & Oncology Authors: Chlebowski RT Tags: Clin Breast Cancer Source Type: research

High Expression of Class III β-Tubulin Predicts Good Response to Neoadjuvant Taxane and Doxorubicin/Cyclophosphamide-Based Chemotherapy in Estrogen Receptor-Negative Breast Cancer.
CONCLUSION: This study reveals differential βΙΙΙ-tubulin expression in breast cancers of different histologic grades, hormone receptors, and HER2/neu status. It also suggests a potential role for βΙΙΙ-tubulin as a predictive biomarker for response in neoadjuvant chemotherapy for ER(-) breast cancer, which has not been previously reported. These data provide a strong rationale for considering βΙΙΙ-tubulin status and further validation of this marker in a large study. PMID: 23218766 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 5, 2012 Category: Cancer & Oncology Authors: Wang Y, Sparano JA, Fineberg S, Stead L, Sunkara J, Horwitz SB, McDaid HM Tags: Clin Breast Cancer Source Type: research

Making Capecitabine Targeted Therapy for Breast Cancer: Which is the Role of Thymidine Phosphorylase?
Abstract Thymidine phosphorylase (TP) expression has been found to be elevated in various solid tumors where it is likely involved in mechanisms that regulate cell proliferation, apoptosis, and angiogenesis. Based on these properties, it is tempting to hypothesize a potential prognostic role of TP, suggesting that a high TP expression could predict a poor outcome. On the other hand, TP expression has been studied for its role in predicting benefit from treatment with fluoropyrimidine-containing chemotherapy. Several studies have been conducted on breast cancer. The current evidence on the value of TP is not mature...
Source: Clinical Breast Cancer - December 4, 2012 Category: Cancer & Oncology Authors: Bonotto M, Bozza C, Di Loreto C, Osa EO, Poletto E, Puglisi F Tags: Clin Breast Cancer Source Type: research

Achieving Breast Cancer Surgery in a Single Setting With Intraoperative Frozen Section Analysis of the Sentinel Lymph Node.
In this study, we evaluate the efficacy this practice in terms of the accuracy of FS analysis, patient recall rate, and additional time required for FS analysis. MATERIALS AND METHODS: Retrospective review was performed of 586 patients who underwent SLN biopsy at our institution from January 1, 2006 to December 31, 2010. Intraoperative FS analysis was routinely performed in all cases with a preoperative diagnosis of invasive breast cancer and in selected cases of ductal carcinoma in situ according to surgeon preference. RESULTS: The SLN was positive for metastases in 123 (22.7%) patients; this was identified on FS analysis...
Source: Clinical Breast Cancer - December 4, 2012 Category: Cancer & Oncology Authors: Lu Q, Tan EY, Ho B, Teo C, Seah MD, Chen JJ, Chan PM Tags: Clin Breast Cancer Source Type: research

Incidence and Patterns of Distant Metastases for Patients With Early-Stage Breast Cancer After Breast Conservation Treatment.
CONCLUSION: The present study has demonstrated the site-specific risks of metastases. These data support current clinical practice of screening for site-specific metastatic disease after BCT based on concerning patient-specific signs or symptoms. PMID: 23218473 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 4, 2012 Category: Cancer & Oncology Authors: Berman AT, Thukral AD, Hwang WT, Solin LJ, Vapiwala N Tags: Clin Breast Cancer Source Type: research

A Solitary Bone Lesion in a Patient With Previous Breast Cancer and the Importance of Bone Biopsy: A Case Report and a Review of Guidelines.
PMID: 23199805 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 28, 2012 Category: Cancer & Oncology Authors: Schiavon G, Tait DM, Briggs TW, Smith IE Tags: Clin Breast Cancer Source Type: research